Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development
Thermostability, immunogenicity and efficacy data against related viruses may provide rapid starting point for vaccine development
PRINCETON, N.J. , May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
PRINCETON, N.J. , April 28, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader
Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient...
Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is...
Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed its positioning in a landscape where modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism...
ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies will air interviews with BIO-key International, Inc. (Nasdaq:BKYI), 20/20 Biolabs, Inc. (Nasdaq:AIDX), Society Pass Inc. (Nasdaq:SOPA),...
Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment of cutaneous T-cell lymphoma in Oncology...